Archive | .

Evolving Role of TKI Monotherapy
in Front Line Metastatic Clear Cell RCC

Keywords: tyrosine kinase inhibitor, monotherapy, front-line, prognostic classification, IMDC model, sunitinib, cabozantinib.  Corresponding Author: Bradley A. McGregor, MD, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston MA, 02215 Email: Bradley_McGregor@DFCI.HARVARD.EDU   Tyrosine kinase inhibitors (TKI) directed against the Vascular Endothelial Growth Factor (VEGFR) were unquestionably the gold standard for front-line therapy in advanced renal cell carcinoma […]

Continue Reading

Combination Immunotherapy and
Targeted Therapy: Will New Combinations
Raise the Tail of the Survival Curve?

Xin Gao, MD Medical Oncologist Claire and John Bertucci Center     for Genitourinary Cancers Massachusetts General Hospital     Cancer Center Boston, Massachusetts   Keywords: Combination therapy, PD-1/PD-L1, immunotherapy, VEGR/VEGFR, anti-angiogenic therapy Corresponding Author: Xin Gao, MD, Massachusetts General Hospital Cancer Center, Yawkey Building, Suite 7E, 55 Fruit Street, Boston, MA 02114   Tel: […]

Continue Reading

The Landscape of Adjuvant Therapy:
A Controversy in Search of a Consensus

Michael R. Harrison, MD Associate Professor of Medicine Division of Medical Oncology Duke Cancer Institute Duke University Health System Durham, North Carolina   Keywords:adjuvant therapy, locoregional, cytokine therapy, S-TRAC, ARISER, ASSURE, PROTECT, disease-free survival, sunitinib, pazopanib.  Corresponding Author: Michael R. Harrison, MD, Duke Cancer Center 20 Duke Medicine Circle Durham, NC 27710 Email:   […]

Continue Reading